Agno Pharmaceuticals is a leading, global, small molecule Contract Development and Manufacturing Organization (CDMO), catering to the specific needs of the branded pharmaceutical, biotech, generic, and CDMO sectors. Agno Pharmaceuticals is a US-based, end-to-end premier service provider. We specialize in supplying Registered Starting Materials (RSMs), custom Chemical Intermediates, Active Pharmaceutical Ingredients (APIs), highly potent APIs, sterile APIs, and complex Drug Product formulations (including long-acting injectables/implants) to our valued clientele worldwide. Our US-FDA inspected cGMP compliant manufacturing facilities ensures that we are able to provide our services at a level of unparalleled quality and compliance to our customer base.

I lead the North American Business Operations for Ardena where we provided integrated pharmaceutical CDMO services. These included API and drug product manufacturing, logistics and (bio)analytical services to biotech and pharmaceutical customers. The emphasis was on pre-clinical through phase 3.

Responsible for Evotec’s discovery and development contract services supporting novel small molecules and biologics' drug development into the clinic. Leveraging my skills and expertise in driving the revenue generation for Evotec to deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. This is accomplished through closing short-term revenue opportunities and establishing long-term mutually beneficial relationships with clients. By utilizing my experience and understanding the requirements and challenges of drug discovery and development stages, I have been effective at securing and retaining business through professional, consultative, proactive sales activities, directed to decision-makers and decision-influencers at new clients.

Responsible for launching Clyde Biosciences business in the Americas providing their specialized CRO cardiac toxicology screening services. The stem cell-based assay was part of the Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative with the FDA and focused on measuring and interpreting drug effects on cardiac cell function. By developing a market penetration strategy to augment the S7B guidance, Clyde was successful in attracting small through large pharma/biotech companies. The services allow for early preclinical screening of candidate compounds as well as supporting late stage compounds with known cardiac liabilities needing risk assessment. These activities support drug development across a broad array of areas including heart failure, vascular biology, neural, oncology, diabetes and metabolism, immunology and infectious diseases.Major Accomplishments• Lead and coordinate US/CAN Business Development/Sales and Customer Support.• Developed a marketing and sales plan to understand customer needs to create a penetrate strategyand create business within the American safety pharmacology market to address unmet needs fromhistorical approaches.• Worked with the senior management team to build a corporate strategy and implement at a tacticallevel to engage relevant sales channels based on the plan and established sales budget.• Create and manage relationships with KOL’s, consultants and industry professional in the cardiacsafety pharmacology space.• Promote the scientific approach of the unique technology of Clyde by giving scientific presentations,organizing workshops and negotiating with clients on a scientific basis.• Collect customer feedback and relay to management to refine the marketing message and optimizethe service capabilities within the market space.

Responsible for business development of Protea's mass spectrometry imaging services as well as analytical services for biotherapeutic characterization, small molecules/peptide analysis, proteomics, metabolomics, and biomarker discovery & analysis supporting DMPK and preclinical development.Major Accomplishments• Lead the business development and sales growth of services relating to Protea’s positioning in the mass spec imaging market. Segment markets for both MALDI and LAESI imaging and develop strategies to create or take advantage of sales synergies for mass spec imaging and traditional LC/MS based bioanalytical approaches for Tox or PK absorption and distribution studies.• Develop the business for the company’s mass spectrometry LC-MS/MS services portfolio with special focus on life sciences, such as metabolomics, proteomics, protein characterization, protein quantitation, peptide mapping and biomarker discovery and validation through demand generation activities and nurturing customer’s relationship.• Maintaining and further expanding the business pipeline of qualified opportunities into the DMPK and preclinical market segment.• Building and maintaining new and existing client relations.• Attending conferences and exhibitions to represent the company by delivering business & scientific presentations.• Identify new testing needs based on market requests and client directions.

Responsible for corporate business development programs to facilitate preclinical research, GLP-Tox and Phase I-III services growth in the western United States. The primary focus was to expand market share in the preclinical arena, focusing on the IP to IND space, targeting virtual to large-size biotech/pharma companies needing lead choice/optimization, medicinal chemistry, process chemistry, through analytical, bioanalytical/PK, ADME, and toxicology studies in human and animal health areas. Major Accomplishments• Aggressive prospector with a proven track record of launching into new territories and breaking into new accounts by excelling in cold calling. Implemented a strategic approach for identifying prospective customers, designing sales proposals and negotiating win/win scenarios. This resulted in the addition of 6 new high-volume sponsors. • Function as a liaison to support all phases of development – from early discovery research through Phase III and post-approval patent extension programs following all FDA guidances for document preparation and control. • Small Molecule – knowledge on filing NCE first in human, 505(b)(2) applications, as well as Generic first to file experience. • Large Molecule - proteins, peptides, monoclonal antibodies, antibody-drug conjugates (ADC), NCE and Biosimilar, Vaccines development experience. • Support sponsors on assay design and development for LC-MS/MS, ADA, NAb and Biomarker analysis for preclinical or clinical programs.• Provide written and verbal scientific input on study design and implementation for Non-GLP preclinical discovery/research GLP Compliant preclinical ADME/Tox with plasma and tissues expertise as well as Clinical Phase I-III, with PK sample collection kit protocol design and preparation.• Manage proposal preparation to align with study needs and project budget.• Provide contract negations and review CDAs and MSAs for account sponsors.

Created de novo an integrated sales and marketing program for GeneTex that included sales and marketing strategy development and execution within North and South America. This, for the first time, allowed the company to build and grow revenue outside of preexisting OEM business channels and word of mouth sales. Managed our direct sales team as well as our North and South American distribution network. Responsible for targeting, forecasting, compensation program development, key relationship management and senior staff contributions as well as for new product development and marketing that included conventional and digital channels. Major Accomplishments:• Hired and managed the US sales & marketing team with 8 direct reports.• Developed, directed and measured the execution of strategic annual/long-term marketing plans in order to meet and exceed sales and revenue commitments/goals.• Developed the product/business strategy, its pricing and analysis, and performed ongoing business analysis to drive the brand performance.• Constructed work plans, established marketing strategy and conducted forecasts, budget management and control, all within set deadlines.• Efficiently managed offline and online marketing channels, lead generation, advertising campaigns, sales promotion campaigns, publisher relations and collaborative ventures• Hired and managed the US field sales team with 5 regional representatives in key strategic areas. • Formulated and implemented sales initiatives and tracked performance to achieve objectives to enhance organization effectiveness.• Established and managed distributors in US/Canada, Mexico, Brazil and Columbia with a track record of increasing sales year over year.

As a Strategic Account Manager, my responsibilities included leading scientific communications in cooperation with Business Development, Market Assessment and Product/Technology Development efforts to define client requirements and guide the sales and strategic positioning of our cell based assays product portfolio. Major Accomplishments• Hired and managed global technical sales team to drive worldwide BioFlux sales goals.• Identified, expanded, and maintained strategic key accounts within the vascular biology, inflammation and oncology drug and therapeutic development markets.• Developed strategic business development approaches based on analysis of cellular based assay development pipelines, individual company profiles, and market networking.• Prospecting of new accounts by identifying potential opportunities and interfacing with relevant contacts.• In collaboration with company team members, presented company capabilities to potential key accounts with respect to specific assays, drug targets, and disease indications.• In collaboration with company team members, presented company capabilities to potential key accounts with respect to specific assays, drug targets, and disease indications.• Worked with clients and service teams to develop proposals, draft and negotiate contract terms, and close business deals.

Responsibilities included the development of product concept innovation that involved the creation of new products and product line extensions centered on human and murine embryonic stem cells and adult neural and mesenchymal stem cells. Oversaw the development of new products from conception through transfer to manufacturing as well as functioning as an internal technical consultant for other members of the company. The position also required the contribution to technical publications and patent applications.Major Accomplishments:• Responsible for the development of stem cell isolation kits, stem cell media, characterization kits and reporter cell line. • Published Cellutions Newsletter article 2007 volume 1 “Isolation of Cardiac Stem Cells and their Differentiation into Cardiomyocytes”. • Developed business collaborations with academic laboratories to facilitate the isolation of human cardiac stem cells for therapeutic transplantation.• Presented a variety of internal seminars to train and educate sales, technical support and product management staff on stem cell departmental products.• Spearheaded the creation of a new confocal microscopy core, which required preparing budget justifications and presentations to senior stakeholders. Evaluated microscopy equipment from competitor companies. • I was an integral team member for the development and testing of the Guava flow cytometry stem cell characterization kits.

Responsible for the tutelage of undergraduate students in the biological sciences. Prepared and taught lesson plans. Responsible for grading and troubleshooting problem areas with students. Major Accomplishments:Taught the following courses through the Department of Biological Sciences.•2006(Spring term) Intermediate Molecular Biology: BIOL 309•2006(Fall term) Biology of Aging: BIOL 306•2007(Spring term) Advanced Molecular Biology: BIOL 413•Invited editor for Molecular Cell Biology, 6th edition Harvey Lodish et al.

Research centered on developing cutting-edge stem cell based therapeutic approaches for breast and glioma cancers. This was accomplished through elucidating the molecular and biochemical contribution of Phosphoinositide-3 kinase on the regulation of neural and mesenchymal stem cell tumor targeting towards invasive cancers.Major Accomplishments:• Oversaw laboratory management to ensure efficient day-to-day activities of junior laboratory members.• Invited speaker at Beckman Symposium and California State University at Fullerton.• Contributed significant support for my principle investigator’s production and submission of external grants for maintaining laboratory funding• Participated in mentoring in the City of Hope Summer Student Research Program and Joint Mentoring Honors Thesis Research Program through City of Hope and Clermont Collages.